Compare AdaptHealth Corp (AHCO) vs Delta Air Lines, Inc. (DAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AdaptHealth Corp vs Delta Air Lines, Inc. — how do they compare? AdaptHealth Corp trades at $5.66 (market cap $759.10M), while Delta Air Lines, Inc. trades at $90.12 (market cap $58.67B). The key difference: Delta Air Lines, Inc. is far larger — about 77.3× AdaptHealth Corp's market cap, and Delta Air Lines, Inc. pays a 0.87% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.
| AHCO | DAL | |
|---|---|---|
Market Cap | $759.10M | $58.67B |
Sector | Health | Industrials |
52-Week High | $13.38 | $93.66 |
52-Week Low | $5.22 | $55.65 |
Enterprise Value | $2.78B | $73.99B |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AdaptHealth Corp. (AHCO) trades at $5.69, down 5.87% in the last 24 hours, reflecting negative sentiment after recent earnings misses and lowered guidance. The stock shows a bearish technical signal with support near $5, while fundamentals reveal revenue of $3.24 billion in 2025 but a net loss of $70.79 million, with profitability metrics like net margin at -6.82% indicating operational challenges. Recent news highlights multiple law firm investigations into potential securities fraud following disappointing Q2 2026 results.
The outlook for AHCO is cautious due to persistent earnings underperformance and rising costs from fixed-price contracts. While analyst consensus remains bullish with a $11.00 price target, significant risks include ongoing legal scrutiny, margin pressure, and execution uncertainties. Investors should weigh the high institutional buy ratings against fundamental weaknesses and recent negative developments.
Delta Air Lines (DAL) trades at $91.34, down 0.7% today, amid a bullish technical trend and strong fundamentals. The stock shows robust earnings beats in recent quarters, with Q3 2026 EPS expected at $2.19. Valuation metrics like a P/E of 15.15 and P/S of 0.88 suggest potential undervaluation, while cash flow trends improved to a net positive $1.08B in 2025. Recent news highlights insider sales but also strong Q2 results and industry tailwinds.
Outlook remains positive with an 81.82% analyst buy rating and consensus price target of $108.27, implying ~18% upside. Key risks include fuel cost volatility and competitive pressures, but DAL's premium travel demand and loyalty program strength support growth. Investors should weigh solid fundamentals against macroeconomic sensitivities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AdaptHealth Corp
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →
